HK1203200A1 - 取代的***並吡啶及其作為 抑制劑的用途 - Google Patents

取代的***並吡啶及其作為 抑制劑的用途

Info

Publication number
HK1203200A1
HK1203200A1 HK15103784.7A HK15103784A HK1203200A1 HK 1203200 A1 HK1203200 A1 HK 1203200A1 HK 15103784 A HK15103784 A HK 15103784A HK 1203200 A1 HK1203200 A1 HK 1203200A1
Authority
HK
Hong Kong
Prior art keywords
ttk
inhibitors
substituted triazolopyridines
triazolopyridines
substituted
Prior art date
Application number
HK15103784.7A
Other languages
English (en)
Inventor
‧舒爾策
‧科澤蒙德
‧溫內爾
‧西邁斯特
‧施特科基特
‧布吕寧
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of HK1203200A1 publication Critical patent/HK1203200A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15103784.7A 2011-12-12 2015-04-20 取代的***並吡啶及其作為 抑制劑的用途 HK1203200A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11193011 2011-12-12
PCT/EP2012/074978 WO2013087579A1 (en) 2011-12-12 2012-12-10 Substituted triazolopyridines and their use as ttk inhibitors

Publications (1)

Publication Number Publication Date
HK1203200A1 true HK1203200A1 (zh) 2015-10-23

Family

ID=47427291

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103784.7A HK1203200A1 (zh) 2011-12-12 2015-04-20 取代的***並吡啶及其作為 抑制劑的用途

Country Status (40)

Country Link
US (1) US9663510B2 (zh)
EP (1) EP2791136B1 (zh)
JP (1) JP6181664B2 (zh)
KR (1) KR20140105552A (zh)
CN (1) CN104114552B (zh)
AP (1) AP4017A (zh)
AR (1) AR089143A1 (zh)
AU (1) AU2012350751B2 (zh)
BR (1) BR112014014184A2 (zh)
CA (1) CA2858683A1 (zh)
CL (1) CL2014001546A1 (zh)
CO (1) CO6980657A2 (zh)
CR (1) CR20140275A (zh)
CU (1) CU20140068A7 (zh)
CY (1) CY1116958T1 (zh)
DK (1) DK2791136T3 (zh)
DO (1) DOP2014000133A (zh)
EC (1) ECSP14004812A (zh)
ES (1) ES2550677T3 (zh)
GT (1) GT201400111A (zh)
HK (1) HK1203200A1 (zh)
HR (1) HRP20151103T1 (zh)
HU (1) HUE025937T2 (zh)
IL (1) IL232930A (zh)
JO (1) JO3111B1 (zh)
MA (1) MA35826B1 (zh)
MX (1) MX2014007057A (zh)
PE (1) PE20141597A1 (zh)
PH (1) PH12014501319A1 (zh)
PL (1) PL2791136T3 (zh)
PT (1) PT2791136E (zh)
RS (1) RS54288B1 (zh)
RU (1) RU2632464C1 (zh)
SG (1) SG11201402820SA (zh)
SI (1) SI2791136T1 (zh)
TN (1) TN2014000254A1 (zh)
UA (1) UA112096C2 (zh)
UY (1) UY34515A (zh)
WO (1) WO2013087579A1 (zh)
ZA (1) ZA201404031B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150040845A (ko) * 2012-07-10 2015-04-15 바이엘 파마 악티엔게젤샤프트 치환된 트리아졸로피리딘을 제조하는 방법
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
KR20160018534A (ko) * 2013-06-11 2016-02-17 바이엘 파마 악티엔게젤샤프트 Mps-1 키나제 억제제 및 유사분열 억제제를 포함하는 암의 치료를 위한 조합물
HUE033131T2 (en) * 2013-06-11 2017-11-28 Bayer Pharma AG Derivatives of substituted triazolopyridines
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
CN106414447A (zh) * 2014-05-19 2017-02-15 Udc 爱尔兰有限责任公司 具高效率的荧光有机发光元件
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
EP3233127A1 (de) 2014-12-15 2017-10-25 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit aglycosylierten anti-tweakrantikörpern
CN105985241A (zh) * 2015-01-27 2016-10-05 邵阳学院 α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用
JP2018525334A (ja) 2015-06-23 2018-09-06 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｔｗｅａｋｒ抗体との抗体薬物複合体
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
US10968216B2 (en) 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
EP3558387B1 (de) 2016-12-21 2021-10-20 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
CN106831555B (zh) * 2017-01-22 2019-09-24 中国农业大学 吡啶酰胺类化合物及其制备方法与应用
CN112514092A (zh) 2018-07-23 2021-03-16 三星显示有限公司 有机发光装置
US20230046077A1 (en) 2019-02-07 2023-02-16 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
KR102661468B1 (ko) 2019-02-15 2024-04-30 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 전자 장치
KR20210059153A (ko) 2019-11-14 2021-05-25 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 장치
WO2023167549A1 (en) * 2022-03-04 2023-09-07 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
US7226941B2 (en) 2003-06-30 2007-06-05 Hif Bio, Inc. Compound for treating angiogenesis
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
WO2008025821A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
US8053574B2 (en) 2007-07-18 2011-11-08 Novartis Ag Organic compounds
EP2212326A1 (en) 2007-08-23 2010-08-04 AstraZeneca AB 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2009027283A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009068482A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
EP2396324A1 (en) 2009-02-13 2011-12-21 Fovea Pharmaceuticals Ý1, 2, 4¨triazolo ý1, 5 -a¨pyridines as kinase inhibitors
WO2010124826A1 (en) 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
CA2784769A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted triazole derivatives as gamma secretase modulators
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
JP2011246389A (ja) * 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
KR20140025470A (ko) * 2011-04-21 2014-03-04 바이엘 인텔렉쳐 프로퍼티 게엠베하 트리아졸로피리딘

Also Published As

Publication number Publication date
GT201400111A (es) 2015-11-30
PT2791136E (pt) 2015-11-04
PH12014501319A1 (en) 2014-09-08
AP4017A (en) 2017-01-28
CN104114552A (zh) 2014-10-22
JP2015500308A (ja) 2015-01-05
CR20140275A (es) 2014-08-13
JO3111B1 (ar) 2017-09-20
CY1116958T1 (el) 2017-04-05
PE20141597A1 (es) 2014-11-07
CN104114552B (zh) 2016-12-28
RU2632464C1 (ru) 2017-10-05
SG11201402820SA (en) 2014-06-27
ZA201404031B (en) 2016-09-28
AP2014007731A0 (en) 2014-06-30
MA35826B1 (fr) 2014-12-01
IL232930A0 (en) 2014-08-03
SI2791136T1 (sl) 2015-11-30
US9663510B2 (en) 2017-05-30
IL232930A (en) 2016-07-31
ECSP14004812A (es) 2015-11-30
JP6181664B2 (ja) 2017-08-16
CO6980657A2 (es) 2014-06-27
CA2858683A1 (en) 2013-06-20
CU20140068A7 (es) 2014-12-26
HUE025937T2 (en) 2016-05-30
EP2791136A1 (en) 2014-10-22
ES2550677T3 (es) 2015-11-11
DK2791136T3 (en) 2015-10-26
BR112014014184A2 (pt) 2017-06-13
AU2012350751A1 (en) 2014-06-26
AR089143A1 (es) 2014-07-30
EP2791136B1 (en) 2015-07-29
RS54288B1 (en) 2016-02-29
AU2012350751B2 (en) 2017-07-06
PL2791136T3 (pl) 2015-12-31
KR20140105552A (ko) 2014-09-01
US20150210683A1 (en) 2015-07-30
MX2014007057A (es) 2014-08-08
TN2014000254A1 (en) 2015-09-30
UA112096C2 (uk) 2016-07-25
UY34515A (es) 2013-07-31
HRP20151103T1 (en) 2015-11-20
NZ625815A (en) 2016-07-29
DOP2014000133A (es) 2014-07-31
WO2013087579A1 (en) 2013-06-20
CL2014001546A1 (es) 2014-10-24

Similar Documents

Publication Publication Date Title
HRP20151103T1 (en) Substituted triazolopyridines and their use as ttk inhibitors
HK1202879A1 (zh) 使用 抑制劑的組合物和方法
HK1199726A1 (zh) 犬尿氨酸- -單加氧酶抑制劑、其藥物組合物及其使用方法
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
HK1208453A1 (zh) 取代的吡啶並嘧啶化合物及其作為 抑制劑的用途
HK1198827A1 (zh) 抑制劑及其用途
HK1199705A1 (zh) 犬尿氨酸- -單加氧酶抑制劑、藥物組合物及其使用方法
HK1206264A1 (zh) 犬尿氨酸- -單加氧酶抑制劑、其藥物組合物及其使用方法
HK1202112A1 (zh) 端錨聚合酶的吡咯並嘧啶酮和吡咯並吡啶酮抑制劑
HRP20160735T1 (hr) Derivati tetrahidro-kinazolinona kao inhibitori tank i parp
EP2709991A4 (en) USE OF CXCR4 ANTAGONISTS
GB201111705D0 (en) Compounds and their use
IL228436A0 (en) Pyridopyrazine history and their use
HK1198365A1 (zh) 咪唑並吡啶化合物、組合物和使用方法
HK1201066A1 (zh) 端錨聚合酶的吡喃並吡啶酮抑制劑
EP2688901A4 (en) INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10
GB201114448D0 (en) Compounds and their use
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
HK1198587A1 (zh) 異噻唑並吡啶- -甲酰胺和它們作為藥物的用途
PT2709991T (pt) Uso de antagonistas de cxcr4 para tratar síndrome de whim, mielocatexia, neutropenia e linfocitopenia
GB201104444D0 (en) Compounds and their use

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211212